Schizophrenia drug trial questioned
27 August 2008
 The US Food and Drug Administration (FDA) has requested more data on a schizophrenia treatment developed by Johnson & Johnson (J&J). J&J has been sent a "complete response" letter from the FDA, but the firm has not been ordered to carry out a second trial for the new drug.The company said the letter outlined further questions that needed to be addressed.During J&J's clinical trial of the intramuscular drug paliperidone palmitate, which is taken once a month, psychiatrist David Hough found the anti-psychotic reduced the likelihood of a relapse in patients suffering from schizophrenia to between ten and 15 per cent.J&J halted the drug trial early because of the clear benefits of the drug, which was tested against a placebo.Paliperidone palmitate uses patented NanoCrystal technology developed by Elan Pharma International.If J&J comply with the FDA's requests paliperidone palmitate could provide a new treatment for patients suffering from schizophrenia in the near future, according to webmd.com.  © Adfero Ltd
© 2008 Adfero Ltd. All rights reserved. Any views and opinions expressed in news articles are not those of Craegmoor Limited and its associated companies. News supplied by Adfero DirectNews.
Bookmark with:
What are these?
 Delicious
 Digg
 reddit
 Facebook
 StumbleUpon
Related stories
02/12/2008 'Higher rate of mental illness among western homeless'
Homeless people in western countries are more prone to suffering from some form of mental illness than members of the general population, according to new research.
02/12/2008 UCL develops depression test
University College London (UCL) has developed a new universal test to gauge the risks of someone succumbing to major depression.
01/12/2008 'Health care improving but stigma remains'
Progress in mental health services in Wales is being made, but stigma and bureaucracy remains a problem, it has been reported.
01/12/2008 Meditation is 'effective medication for depression'
Meditation techniques are just as effective at combating depression as prescription medication, according to new research.
01/12/2008 Mental health services to be centralised in Ayrshire
Mental health services in Ayrshire and Arran are set to be centralised at the Ayrshire Central Hospital in Irvine as part of a £53 million plan.
|